** Shares of drugmaker Pfizer PFE.N rise ~2% to $26.72 premarket
** Co reports Q4 adj. profit of 63 cents per share, above analysts' est. of 47 cents, according to data compiled by LSEG, driven by strong sales of its heart disease drug and COVID-19 vaccine sales
** Co posts Q4 sales of $17.76 bln vs analysts' est. of $17.36 bln - LSEG
** Q4 sales of heart disease drug, sold as Vyndaqel and Vyndamax, came in at $1.55 bln, above estimates of $1.48 bln - LSEG
** COVID vaccine Comirnaty brought in sales of $3.38 bln, above analysts' est. of $3.10 bln - LSEG
** PFE fell 10.8% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。